New Israeli COVID -19 Treatment Seemingly Successful with First Two Patients
The first two patients who were treated with a new Israeli treatment for the novel COVID-19 after testing positive have shown significant improvement, with one of them even being removed from the intensive care unit (ICU) within days of treatment.
Israeli biopharmaceutical RedHill Biopharma Ltd. administered their experimental drug, Opaganib, in Israel for the first time last week. The first two patients treated, according to the company, have demonstrated significant improvement through clinical trial within mere days of treatment.
“We are very encouraged by the preliminary findings showing clinical improvement in the first COVID-19 patients treated with Opaganib, which further supports its safety and potential benefit to patients,” said Medical Director at RedHill, Mark L. Levitt, MD, Ph.D.
“Our hope is that the unique mechanism of action of Opaganib, with both anti-viral and anti-inflammatory activity, will help COVID-19 patients by reducing lung inflammation, and thus preventing the disease from progressing to a stage which requires mechanical ventilation. Importantly, Opaganib is targeting a critical host factor that the coronavirus is unlikely to evade via mutation in possible future outbreaks of the pandemic.”
Read More: Jerusalem Post